Cover Image

PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma

Glioblastoma is the most frequent and a particularly malignant primary brain tumor with no efficacy-proven standard therapy for recurrence. It has recently been discovered that excitatory synapses of the AMPA-receptor subtype form between non-malignant brain neurons and tumor cells. This neuron-tumo...

Full description

Saved in:
Bibliographic Details
Main Authors: Heuer, Sophie (Author) , Burghaus, Ina (Author) , Gose, Maria (Author) , Keßler, Tobias (Author) , Sahm, Felix (Author) , Vollmuth, Philipp (Author) , Venkataramani, Varun (Author) , Hoffmann, Dirk C. (Author) , Schlesner, Matthias (Author) , Ratliff, Miriam (Author) , Hopf, Carsten (Author) , Herrlinger, Ulrich (Author) , Ricklefs, Franz Lennard (Author) , Bendszus, Martin (Author) , Krieg, Sandro (Author) , Wick, Antje (Author) , Wick, Wolfgang (Author) , Winkler, Frank (Author)
Format: Article (Journal)
Language:English
Published: 26 January 2024
In: BMC cancer
Year: 2024, Volume: 24, Issue: 1, Pages: 1-13
ISSN:1471-2407
DOI:10.1186/s12885-024-11846-1
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12885-024-11846-1
Verlag, kostenfrei, Volltext: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-024-11846-1
Verlag, kostenfrei, Volltext: https://pmc.ncbi.nlm.nih.gov/articles/PMC10811925
Get full text
Author Notes:Sophie Heuer, Ina Burghaus, Maria Gose, Tobias Kessler, Felix Sahm, Philipp Vollmuth, Varun Venkataramani, Dirk Hoffmann, Matthias Schlesner, Miriam Ratliff, Carsten Hopf, Ulrich Herrlinger, Franz Ricklefs, Martin Bendszus, Sandro M. Krieg, Antje Wick, Wolfgang Wick, Frank Winkler
Description
Summary:Glioblastoma is the most frequent and a particularly malignant primary brain tumor with no efficacy-proven standard therapy for recurrence. It has recently been discovered that excitatory synapses of the AMPA-receptor subtype form between non-malignant brain neurons and tumor cells. This neuron-tumor network connectivity contributed to glioma progression and could be efficiently targeted with the EMA/FDA approved antiepileptic AMPA receptor inhibitor perampanel in preclinical studies. The PerSurge trial was designed to test the clinical potential of perampanel to reduce tumor cell network connectivity and tumor growth with an extended window-of-opportunity concept.
Item Description:Gesehen am 17.01.2024
Physical Description:Online Resource
ISSN:1471-2407
DOI:10.1186/s12885-024-11846-1

Similar Items